Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has scheduled its second quarter 2025 financial results announcement for Monday, August 4, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. A replay of the webcast will be available for at least 30 days on the company's investor relations website.
Krystal Biotech (NASDAQ: KRYS), un'azienda biotecnologica in fase commerciale, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per lunedì 4 agosto 2025, prima dell'apertura dei mercati statunitensi.
La società terrà una conference call e una diretta web alle 8:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento sul business. La registrazione della diretta sarà disponibile per almeno 30 giorni sul sito web delle relazioni con gli investitori dell'azienda.
Krystal Biotech (NASDAQ: KRYS), una empresa biotecnológica en etapa comercial, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el lunes 4 de agosto de 2025, antes de la apertura de los mercados en EE. UU.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:30 am ET del mismo día para discutir los resultados y ofrecer una actualización del negocio. La repetición de la transmisión estará disponible durante al menos 30 días en el sitio web de relaciones con inversionistas de la empresa.
Krystal Biotech (NASDAQ: KRYS)는 상업 단계에 있는 생명공학 회사로서, 2025년 8월 4일 월요일 미국 시장 개장 전 2025년 2분기 재무 실적 발표를 예정하고 있습니다.
회사는 같은 날 동부 표준시 오전 8시 30분에 실적 발표 및 사업 업데이트를 위한 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 웹캐스트 녹화는 회사 투자자 관계 웹사이트에서 최소 30일 동안 다시보기로 제공됩니다.
Krystal Biotech (NASDAQ : KRYS), une entreprise biotechnologique en phase commerciale, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le lundi 4 août 2025, avant l'ouverture des marchés américains.
La société organisera une conférence téléphonique et une diffusion en direct à 8h30 ET le même jour pour discuter des résultats et fournir une mise à jour commerciale. La rediffusion de la diffusion sera disponible pendant au moins 30 jours sur le site web des relations investisseurs de l'entreprise.
Krystal Biotech (NASDAQ: KRYS), ein Biotechnologieunternehmen in der kommerziellen Phase, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Montag, den 4. August 2025 geplant, und zwar vor Öffnung der US-Märkte.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben. Eine Aufzeichnung des Webcasts wird mindestens 30 Tage lang auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, August 4, 2025, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52772.
For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Krystal Biotech (KRYS) report Q2 2025 earnings?
What time is Krystal Biotech's Q2 2025 earnings call?
How can I access Krystal Biotech's Q2 2025 earnings webcast?
Where can I find the replay of Krystal Biotech's Q2 2025 earnings call?
